Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Apple Turns 50: From Garage Startup to AI Crossroads 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Britain Courts Anthropic Amid US Defense Department Dispute 
BURNABY, British Columbia, June 27, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, announced that it will host a conference call and live audio webcast at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) today to discuss the topline results from the TV-45070 Phase 2b clinical trial in post-herpetic neuralgia (PHN).
A link to the live audio webcast of the presentation will be available on the investors section of Xenon's website at investor.xenon-pharma.com and will be available for replay following the event. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 47072480.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Investor/Media Contact: Jodi Regts VP, Corporate Affairs & Investor Relations Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: [email protected]
